Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Genetic variations associated with drug resistance
US9879267B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9879267-B2 |
| Application number | US-92242009-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2009 |
| Priority date | Mar 14, 2008 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating breast cancer, comprising (a) determining, in a tissue sample obtained from a human patient with HER2-positive breast cancer who had shown prior progression on HER2-directed therapy, a copy number of an ABCC3 (ATP-Binding Cassette, Sub-Family C, Member 3) gene or an ABCC3 gene amplification value, relative to an amplification value of a centromere 17 (CEP17) gene in the same tissue sample, by fluorescence in situ hybridization (FISH), and (b) administering to the patient whose breast cancer is characterized by an ABCC3 gene copy number of less than 3 or an ABCC3 gene amplification value of less than 1.8 relative to an amplification value of a CEP17 gene an effective amount of a conjugate of trastuzumab and N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)maytansine (DM1), or a conjugate of trastuzumab and monomethyl auristatin E (MMAE). 2. The method of claim 1 , wherein said conjugate is trastuzumab-N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC)-DM1 (T-DM1).
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
for lactation disorders, e.g. galactorrhoea · CPC title
- C12N15/1138Primary
against receptors or cell surface proteins · CPC title
the tumour determinant being from breast cancer cell · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9879267B2 cover?
- Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
- Who is the assignee on this patent?
- Lackner Mark, Amler Lukas C, Cavet Guy, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1138. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).